Angiotensin IV analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-30. Numbers and descriptions here follow the published literature rather than marketing material.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
The cells of fungi have in addition to the shared eukaryotic organelles a spitzenkörper in their endomembrane system, associated with hyphal tip growth. It is a phase-dark body that is composed of an aggregation of membrane-bound vesicles containing cell wall components, serving as a point of assemblage and release of such components intermediate between the Golgi and the cell membrane. The spitzenkörper is motile and generates new hyphal tip growth as it moves forward. The cell walls of fungi are uniquely made of a chitin-glucan complex. Chloroplasts are not found in fungal cells, their pigments are instead associated with their cell walls.
Antithrombin (AT) is a small glycoprotein that inactivates several enzymes of the coagulation system. It is a 464-amino-acid protein produced by the liver. It contains three disulfide bonds and a total of four possible glycosylation sites. α-Antithrombin is the dominant form of antithrombin found in blood plasma and has an oligosaccharide occupying each of its four glycosylation sites. A single glycosylation site remains consistently un-occupied in the minor form of antithrombin, β-antithrombin. Its activity is increased manyfold by the anticoagulant drug heparin, which enhances the binding of antithrombin to factor IIa (thrombin) and factor Xa.
=== We–Wh === Edwin C. Webb (1921–2006). British (later Australian) biochemist at the University of Queensland and Macquarie University. Editor of Enzyme Nomenclature until 1992. Gregorio Weber (1916–1997). Argentinian spectroscopist at the University of Illinois, who pioneered the application of fluorescence spectroscopy to the biological sciences. Member Natl. Acad. Sci. USA, National Academy of Sciences of Argentina. Stephen C. West FRS (b. 1952). British biochemist at the Francis Crick Institute, London, known for his work on DNA recombination and repair. Foreign Associate Natl. Acad. Sci. USA. Hans Westerhoff (b. 1953). Dutch biochemist at the Universities of Amsterdam and of Manchester, known for work in systems biology and metabolic regulation. Frank Henry Westheimer (1912–2007). American chemist at Harvard who did pioneering work in physical organic chemistry, applying techniques from physical to organic chemistry and integrating the two fields. Member Natl. Acad. Sci. USA. John Westley (b. 1927). American enzymologist at the University of Chicago known for work on rhodanese and sulfurtransferases in general. Frederick Whatley (1924–2020). British botanist and biochemist at the University of Sydney known for work on photosynthesis. William Joseph Whelan FRS (1924–2021). British-American biochemist at the University of Miami, who worked on the structure of glycogen, and discovered the protein glycogenin at its core. He was very active in the creation of international organizations, including the IUB (now IUBMB) and FEBS.
=== Luminous flux: watt equivalent === With the phaseout of the incandescent lamp in the United States and European Union in the early 21st century, manufacturers and sellers of more energy-efficient lamps have compared the visible light output of their lamps to commonly used incandescent lamp sizes with the watt equivalent or watt incandescent replacement (usually with a lowercase w as a unit symbol, as opposed to capital W for the actual wattage). 1 watt incandescent replacement corresponds to 15 lumens. Thus, a 72-watt halogen lamp, a 23-watt compact fluorescent lamp and a 14-watt light-emitting diode lamp, all of which emit 1500 lumens of visible light, are all marketed as "100 watt incandescent replacement" (100w).
As well as with dim sum, many Chinese drink their tea with snacks such as nuts, plums, dried fruit (in particular jujube), small sweets, melon seeds, and waxberry. China was the earliest country to cultivate and drink tea, which is enjoyed by people from all social classes. Tea processing began after the Qin and Han dynasties. The different types of Chinese tea include red (known as "black tea" outside of East Asia), white, green, yellow, oolong, and black (often called "dark tea" in English to differentiate it from "black tea"). Chinese tea is often classified into several different categories according to the variety of the tea plant from which it is sourced, the region in which it is grown, and the method of production used. Flavored and scented teas originated in China. Jasmine, osmanthus, chrysanthemum, and ginseng are popular varieties. Historically, compressed tea dominated and powdered tea known as matcha would be made from it. This was later supplanted by loose-leaf tea. Fermented tea drinks like kombucha are believed to originate in China, but kombucha is now better known outside of China than within the country. There are four major tea plantation regions: Jiangbei, Jiangnan, Huanan and the southwestern region. Well known types of green tea include Longjing, Huangshan Maofeng, Bilochun, Putuofeng Cha, and Liu'an Guapian. China is the world's largest exporter of green tea. One of the most ubiquitous accessories in modern China, after a wallet or purse and an umbrella, is a double-walled insulated glass thermos with tea leaves in the top behind a strainer.
Sources: en.wikipedia.org
Nutty Professor II: The Klumps at IMDb Nutty Professor II: The Klumps at the TCM Movie Database (archived) Nutty Professor II: The Klumps at the AFI Catalog of Feature Films Nutty Professor II: The Klumps at Box Office Mojo Nutty Professor II: The Klumps at Rotten Tomatoes Nutty Professor II: The Klumps at Metacritic
One of the more likely modes of defense is damage to microbial DNA. Studies using Salmonella demonstrated that DNA repair mechanisms were required to resist killing by ROS. A role for ROS in antiviral defense mechanisms has been demonstrated via Rig-like helicase-1 and mitochondrial antiviral signaling protein. Increased levels of ROS potentiate signaling through this mitochondria-associated antiviral receptor to activate interferon regulatory factor (IRF)-3, IRF-7, and nuclear factor kappa B (NF-κB), resulting in an antiviral state. Respiratory epithelial cells induce mitochondrial ROS in response to influenza infection. This induction of ROS led to the induction of type III interferon and the induction of an antiviral state, limiting viral replication. In host defense against mycobacteria, ROS play a role, although direct killing is likely not the key mechanism; rather, ROS likely affect ROS-dependent signalling controls, such as cytokine production, autophagy, and granuloma formation. Reactive oxygen species are also implicated in activation, anergy and apoptosis of T cells.
Similarly in the United States, the window of administration used to be 3 hours from onset of symptoms, but the newer guidelines also recommend use up to 4.5 hours after symptom onset, depending on the patient's presentation, past medical history, current comorbidities and medication usage. tPA appears to show benefit not only for large artery occlusions but also for lacunar strokes. Since tPA dissolves blood clots, there is risk of hemorrhage with its use.
He also vetoed the "Green Giant", a skyscraper on the South Bank, initiated plans for the National Gallery extension (the winning entry was famously described by Prince Charles as "a monstrous carbuncle" and was never built) and signed off on the building of the Queen Elizabeth II Centre on a bomb site near Westminster; when he was unable to secure private funding as planned the Treasury were forced to pay for the building. Some of the DoE's responsibilities were hived off into English Heritage, a new body.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.